Immunovant (IMVT) Competitors $29.08 -0.35 (-1.19%) (As of 09/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMVT vs. VVNT, UTZ, ADV, CCIV, HYLN, VTRS, RDY, PCVX, SRPT, and CTLTShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Vivint Smart Home (VVNT), Utz Brands (UTZ), Advantage Solutions (ADV), Churchill Capital Corp IV (CCIV), Hyliion (HYLN), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Catalent (CTLT). Immunovant vs. Vivint Smart Home Utz Brands Advantage Solutions Churchill Capital Corp IV Hyliion Viatris Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Catalent Immunovant (NASDAQ:IMVT) and Vivint Smart Home (NYSE:VVNT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk. Which has more volatility and risk, IMVT or VVNT? Immunovant has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Vivint Smart Home has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Does the media favor IMVT or VVNT? In the previous week, Immunovant had 15 more articles in the media than Vivint Smart Home. MarketBeat recorded 16 mentions for Immunovant and 1 mentions for Vivint Smart Home. Immunovant's average media sentiment score of 0.57 beat Vivint Smart Home's score of 0.00 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivint Smart Home 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMVT or VVNT more profitable? Immunovant has a net margin of 0.00% compared to Vivint Smart Home's net margin of -3.07%. Vivint Smart Home's return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -52.07% -48.25% Vivint Smart Home -3.07%N/A -1.81% Does the MarketBeat Community favor IMVT or VVNT? Immunovant received 76 more outperform votes than Vivint Smart Home when rated by MarketBeat users. Likewise, 77.63% of users gave Immunovant an outperform vote while only 51.85% of users gave Vivint Smart Home an outperform vote. CompanyUnderperformOutperformImmunovantOutperform Votes11877.63% Underperform Votes3422.37% Vivint Smart HomeOutperform Votes4251.85% Underperform Votes3948.15% Do insiders & institutionals have more ownership in IMVT or VVNT? 47.1% of Immunovant shares are owned by institutional investors. 5.9% of Immunovant shares are owned by company insiders. Comparatively, 8.6% of Vivint Smart Home shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, IMVT or VVNT? Vivint Smart Home has higher revenue and earnings than Immunovant. Vivint Smart Home is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$259.34M-$1.90-15.49Vivint Smart Home$1.68B1.53-$51.73M-$0.24-50.00 Do analysts prefer IMVT or VVNT? Immunovant presently has a consensus price target of $48.40, suggesting a potential upside of 64.46%. Given Immunovant's higher probable upside, equities research analysts plainly believe Immunovant is more favorable than Vivint Smart Home.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Vivint Smart Home 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryImmunovant beats Vivint Smart Home on 9 of the 16 factors compared between the two stocks. Ad Paradigm Press Is A Starlink IPO Coming In 2024?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.30B$3.07B$5.54B$8.22BDividend YieldN/A1.98%4.34%4.09%P/E Ratio-15.4928.53146.2218.67Price / SalesN/A252.661,907.9968.87Price / CashN/A148.4036.5531.81Price / Book6.923.904.854.53Net Income-$259.34M-$45.56M$114.69M$224.17M7 Day Performance-0.98%1.35%4.41%4.47%1 Month Performance-2.06%16.93%8.26%7.12%1 Year Performance34.94%13.39%28.67%10.65% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVNTVivint Smart Home0 of 5 stars0.00 / 5 stars$12.00flatN/A+0.0%$2.58B$1.68B-50.0011,000News CoverageHigh Trading VolumeUTZUtz Brands3.2853 of 5 stars3.29 / 5 stars$17.52+1.3%$20.17+15.1%+23.5%$2.47B$1.43B-70.083,654ADVAdvantage Solutions1.5354 of 5 stars1.54 / 5 stars$3.67+1.1%$4.00+9.0%+36.7%$1.18B$4.07B-52.4270,000Positive NewsCCIVChurchill Capital Corp IV0 of 5 stars0.00 / 5 stars$3.91-1.8%N/A-36.3%$1.01BN/A0.00147,000Gap DownHYLNHyliion0.4824 of 5 stars0.48 / 5 stars$1.95+4.3%$1.50-23.1%+81.1%$338.48M$670,000.00-3.20250Gap UpVTRSViatris1.2717 of 5 stars1.27 / 5 stars$11.75+3.6%$12.33+5.0%+20.9%$13.99B$15.24B-195.8338,000RDYDr. Reddy's Laboratories1.4574 of 5 stars1.46 / 5 stars$80.25+1.2%$87.00+8.4%+14.0%$13.39B$288.51B19.9127,048PCVXVaxcyte3.456 of 5 stars3.46 / 5 stars$114.13+0.5%$147.50+29.2%+120.9%$12.42BN/A-26.67160SRPTSarepta Therapeutics4.9089 of 5 stars4.91 / 5 stars$125.34-2.4%$186.22+48.6%+5.0%$11.85B$1.50B1,139.451,314Analyst ForecastPositive NewsCTLTCatalent3.0774 of 5 stars3.08 / 5 stars$59.69+0.1%$58.08-2.7%+22.4%$10.80B$4.38B-9.7917,800Short Interest ↑ Related Companies and Tools Related Companies: VVNT Competitors UTZ Competitors ADV Competitors CCIV Competitors HYLN Competitors VTRS Competitors RDY Competitors PCVX Competitors SRPT Competitors CTLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMVT) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts